Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan Abbey, MD, along with research partners in the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas, recently published a case series of 24 eyes that received a fluocinolone intravitreal implant (YUTIQ 0.18 mg) to manage CME after vitrectomy surgery. Dr. Abbey and his colleagues found a significant improvement in central subfield thickness on optical coherence tomography (OCT) and a significant reduction in treatment burden. The published article, “Injectable Fluocinolone Implant for the Management of Chronic Postsurgical Cystoid Macular Edema in Vitrectomized Eyes,” appears in the October 2023 issue of the medical journal RETINA.

Dr. Abbey cares for patients in our Dallas Main and Rockwall offices and also serves as Texas Retina’s Director of Research for Dallas. You can learn more about him here.